Instrument Inactif

Communiqués Decibel Therapeutics, Inc.

Actions

DBTX

US24343R1068

Recherche biotechnologique et médicale

Communiqués

25/09/23	Decibel Therapeutics : Acquisition/Asset Disposal - Form 8-K	PU
05/09/23	DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX	BU
14/08/23	Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update	AQ
12/08/23	DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX	BU
11/08/23	Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update	GL
11/08/23	Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update	AQ
09/08/23	DBTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Decibel Therapeutics to Regeneron Pharmaceuticals	AQ
09/08/23	Decibel Therapeutics : TENDER AND SUPPORT AGREEMENT - Form 8-K	PU
13/06/23	DECIBEL THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
05/06/23	Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference	AQ
02/06/23	Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference	GL
01/06/23	Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting	GL
17/05/23	Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit	GL
17/05/23	Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit	AQ
15/05/23	Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO	AQ
15/05/23	Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update	AQ
15/05/23	Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update	GL
12/05/23	Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO	AQ
12/05/23	Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO	GL
10/05/23	Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting	GL
06/04/23	DECIBEL THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
30/03/23	Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO	GL
29/03/23	Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks, Genomic Medicines and Rare Disease Days	AQ
28/03/23	Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks \| Genomic Medicines and Rare Disease Days	GL
21/03/23	DECIBEL THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ